TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3512419

Group type: EXPERIMENTAL
Intervention: Oral acyclovir for 42 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral acyclovir for five days followed by placebo for 37 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with infections due to HSV I
Number of subjects: 60
Study: 30573023

Group type: EXPERIMENTAL
Intervention: varenicline + naltrexone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: varenicline, naltrexone, or varenicline + naltrexone
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 120
Study: 26916095

Group type: EXPERIMENTAL
Intervention: Continuation of taxane plus bevacizumab (T + BEV)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Maintenance therapy with exemestane plus bevacizumab (E + BEV)
Number of subjects: 117
Study: 23892625

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IUI (n = 180)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Classical IUI (n = 207)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IUI by senior physician
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IUI by junior physician
Number of subjects: 387

Group type: COMPARATOR
Intervention: Classical IUI by senior physician
Number of subjects: 387
Study: 24378269

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate injection (GVO)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Band ligation (GVL)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 37
Study: 20959009

Group type: EXPERIMENTAL
Intervention: Diabetes-specific cognitive behaviour group therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard diabetes education programme
Number of subjects: 104
Study: 18091014

Group type: EXPERIMENTAL
Intervention: Eccentric training program for the calf muscles (6 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 74
Study: 16891014

Group type: EXPERIMENTAL
Intervention: GM-CSF (10 microg/kg body weight, for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 20
Study: 12507187

Group type: EXPERIMENTAL
Intervention: Theophylline therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose routine therapies
Number of subjects: 0
Study: 9718377

Group type: EXPERIMENTAL
Intervention: Epoetin to achieve and maintain a hematocrit of 42 percent
Number of subjects: 1233

Group type: COMPARATOR
Intervention: Epoetin to maintain a hematocrit of 30 percent
Number of subjects: 1233
Study: 7635132

Group type: EXPERIMENTAL
Intervention: Whole-body vertical vibration at 0.5 Hz
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whole-body vertical vibration at 4.0 Hz
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Improved visual feedback in task C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arm support during vibration at 4.0 Hz
Number of subjects: 8
Study: 2692969

Group type: EXPERIMENTAL
Intervention: Etizolam (0.5 mg twice daily for 5 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alprazolam (0.5 mg twice daily for 5 weeks)
Number of subjects: 30
Study: 922750

Group type: COMPARATOR
Intervention: methyl‐CCNU
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: methyl‐CCNU plus 5‐FU
Number of subjects: 49
Study: 30837253

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural analgesia (EDA)
Number of subjects: 80
Study: 29955136

Group type: EXPERIMENTAL
Intervention: XELIRI regimen (irinotecan 180 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1-10 of a 14-day cycle)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Irinotecan monotherapy (irinotecan 180 mg/m2 on day 1 of a 14-day cycle)
Number of subjects: 60
Study: 26728475

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilator assist (NAVA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 25
Study: 25112086

Group type: EXPERIMENTAL
Intervention: Fire needling technique at high stress points
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60
Study: 22810303

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 19538002

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7000
Study: 17998441

Group type: EXPERIMENTAL
Intervention: Daily patient reminder to document seizures
Number of subjects: 91

Group type: COMPARATOR
Intervention: No reminder (control group)
Number of subjects: 91
Study: 15965359

Group type: EXPERIMENTAL
Intervention: Immediate PCI <2 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed PCI (12-72 hours)
Number of subjects: 0
Study: 12468958

Group type: EXPERIMENTAL
Intervention: Controlled-release budesonide (4.5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Deuterium-labelled standard formulation (4.8 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Controlled-release budesonide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Deuterium-labelled standard formulation
Number of subjects: 6
Study: 9800927

Group type: EXPERIMENTAL
Intervention: Psychosocial support by a doula
Number of subjects: 724

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 724
Study: 7710409

Group type: EXPERIMENTAL
Intervention: Akinosi technique
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional mandibular block injection
Number of subjects: 250
Study: 2692948

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 334226

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 40
Study: 31765997

Group type: EXPERIMENTAL
Intervention: Visibility of time pressure (manipulated condition)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Visibility of time pressure (visible condition)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: General performance
Number of subjects: 39
Study: 31016568

Group type: EXPERIMENTAL
Intervention: BAT1706
Number of subjects: 128

Group type: COMPARATOR
Intervention: EU‐BEV
Number of subjects: 128
Study: 27856497

Group type: EXPERIMENTAL
Intervention: Intravenously administered ischemia-tolerant MSCs (itMSCs) at a dosage of 1.5×10^6 cells/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenously administered ischemia-tolerant MSCs (itMSCs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 25393934

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 40
Study: 23512917

Group type: EXPERIMENTAL
Intervention: PGX (15 g day(-1) for 14 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 22101161

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 15 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19186713

Group type: EXPERIMENTAL
Intervention: Acupuncture twice each day (observation group I)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Acupuncture once each day (observation group II)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups received same Chinese drugs and western medicine and electroacupuncture at Jiquan (HT 1), Quchi (LI 11), Hegu (LI 4), Huantiao (GB 30)
Number of subjects: 97
Study: 17577686

Group type: EXPERIMENTAL
Intervention: Amyloid A protein quantification in fat tissue using ELISA with monoclonal antihuman serum amyloid A antibodies.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Congo red stained slides scored by light microscopy in a semiquantitative way (0 to 4+).
Number of subjects: 183

Group type: COMPARATOR
Intervention: Comparison of amyloid A protein values between genders and conditions.
Number of subjects: 183
Study: 15464679

Group type: EXPERIMENTAL
Intervention: Eptifibatide infusion
Number of subjects: 0
Study: 11606173

Group type: EXPERIMENTAL
Intervention: Impaired fasting glycaemia (IFG)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Normal fasting glucose (NFG)
Number of subjects: 657
Study: 9752892

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lisinopril (5 to 10 mg)
Number of subjects: 21
Study: 1901194

Group type: EXPERIMENTAL
Intervention: Lipofundin MCT‐LCT (medium-chain triglycerides)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lipofundin S (long-chain triglycerides)
Number of subjects: 24
Study: 7042592

Group type: EXPERIMENTAL
Intervention: Ambroxol (1000 mg/day for 5 days)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 31419544

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2% applied twice daily for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 14 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2% applied open-label to all affected areas for 28 days after initial treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Crisaborole treatment
Number of subjects: 40
Study: 26768606

Group type: EXPERIMENTAL
Intervention: High-intensity preoperative resistance training programme (8 weeks, 3 days per week)
Number of subjects: 44
Study: 25909892

Group type: EXPERIMENTAL
Intervention: Community paramedics intervention with frequent patient contact and real-time EMR correspondence
Number of subjects: 0
Study: 25163233

Group type: EXPERIMENTAL
Intervention: 0.125% epidural levobupivacaine
Number of subjects: 81

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 81
Study: 22464008

Group type: EXPERIMENTAL
Intervention: Twice daily supportive text messages (n=26)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fortnightly thank you text message (n=28)
Number of subjects: 54
Study: 20372874

Group type: EXPERIMENTAL
Intervention: Sodium chloride (NaCl, 100 mmol/24 h) supplementation during telmisartan treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan plus hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo during telmisartan treatment
Number of subjects: 0
Study: 18756750

Group type: EXPERIMENTAL
Intervention: Enalapril and long-acting nifedipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enalapril and moxonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both combinations
Number of subjects: 40
Study: 15934129

Group type: EXPERIMENTAL
Intervention: Exercise therapy (13 weeks duration)
Number of subjects: 200

Group type: COMPARATOR
Intervention: PT group
Number of subjects: 200

Group type: COMPARATOR
Intervention: NP group
Number of subjects: 200
Study: 12909492

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (Lng‐IUD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Expectant management (surgery only)
Number of subjects: 40
Study: 10588467

Group type: EXPERIMENTAL
Intervention: Seal oil (20 g per day for 42 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vegetable oil (20 g per day for 42 days)
Number of subjects: 19
Study: 9432569

Group type: EXPERIMENTAL
Intervention: Heparan sulfate (100 mg b.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mesoglycan (50 mg b.i.d.)
Number of subjects: 30
Study: 1541143

Group type: EXPERIMENTAL
Intervention: Theophylline (Uniphyllin) 800 mg taken at night for four weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4021762

Group type: EXPERIMENTAL
Intervention: Combined treatment with intensive preoperative irradiation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 102
Study: 31439181

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Counseling with leaflets
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 75
Study: 29935909

Group type: EXPERIMENTAL
Intervention: Bone Pain Education Video (BP‐DVD)
Number of subjects: 300

Group type: COMPARATOR
Intervention: General Education DVD on chemotherapy side effects (GE‐DVD)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study: 26613288

Group type: EXPERIMENTAL
Intervention: Strength at Home Men's Program (SAH‐M)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 135
Study: 25358552

Group type: EXPERIMENTAL
Intervention: Single set (SS; n=14)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Multiple sets (MS; n=13)
Number of subjects: 27
Study: 22893943

Group type: EXPERIMENTAL
Intervention: Additional low threshold psychosocial assistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Additional psychosocial care
Number of subjects: 0
Study: 20124256

Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors (AChIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDA-approved AD or psychiatric medications
Number of subjects: 0
Study: 17646220

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg/d)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 15716217

Group type: EXPERIMENTAL
Intervention: ropinirole (1.4mg HS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 12390903

Group type: EXPERIMENTAL
Intervention: Hospital at Home
Number of subjects: 399

Group type: COMPARATOR
Intervention: Conventional hospital care
Number of subjects: 399
Study: 10091815

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 6595
Study: 7557205

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (ethinylestradiol 50 micrograms/d for 7 days, ethinylestradiol 50 micrograms and desogestrel 125 micrograms/d for 15 days)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Combination of ethinylestradiol 50 micrograms and levonorgestrel 250 micrograms/d for 21 days (Group 1, n = 24)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Lynestrenol 10 mg/d continuously (Group 2, n = 14)
Number of subjects: 172

Group type: COMPARATOR
Intervention: No treatment (Group 3, n = 21)
Number of subjects: 172
Study: 1916501

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (pre-study values)
Number of subjects: 8
Study: 6259008

Group type: EXPERIMENTAL
Intervention: Fiber supplemented diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 17
Study: 31291626

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (ET)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 23
Study: 28179586

Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy (Pre-S CRT, weekly cisplatin 30mg/m2)
Number of subjects: 0
Study: 26530039

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 611

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study: 23085976

Group type: EXPERIMENTAL
Intervention: Moderate dorsiflexion shoes (2°)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neutral shoes (0°)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined tapping-jumping volleyball exercise
Number of subjects: 10
Study: 21821506

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) using ropivacaine, ketorolac, and epinephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intrathecal morphine (0.1 mg)
Number of subjects: 50
Study: 19663522

Group type: EXPERIMENTAL
Intervention: Armodafinil (200 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Modafinil (200 mg/day)
Number of subjects: 52
Study: 17893452

Group type: EXPERIMENTAL
Intervention: ILMA-V
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ILMA-TI
Number of subjects: 30

Group type: COMPARATOR
Intervention: BM-V
Number of subjects: 30

Group type: COMPARATOR
Intervention: LG-TI
Number of subjects: 30
Study: 15486518

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-150 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11573599

Group type: EXPERIMENTAL
Intervention: Oral clonidine (5.5 microg kg(‐1))
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 9544745

Group type: EXPERIMENTAL
Intervention: Simvastatin and bile acid sequestrants
Number of subjects: 42
Study: 7847600

Group type: EXPERIMENTAL
Intervention: 40 mg nalmefene
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10 mg nalmefene
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2841885

Group type: EXPERIMENTAL
Intervention: Fentanyl-group: approximately 0.2 mg/h fentanyl, 2.5 mg/h midazolam, 2 mg/h pancuronium in intermittent doses
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ketamine-group: about 50 mg/h ketamine and 2.5 mg/h midazolam, 2 mg/h pancuronium
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketamine-group
Number of subjects: 16
Study: 31718828

Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg/day)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg/day) and Rosiglitazone (4 mg/day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 204
Study: 29883988

Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (rIPC), 200 mmHg cuff pressure, 4 cycles of occlusion/reperfusion for 5 min each
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: placebo, 120 mmHg cuff pressure, 4 cycles of occlusion/reperfusion for 5 min each
Number of subjects: 10

Group type: COMPARATOR
Intervention: sham control, 10 mmHg pressure, 4 cycles of occlusion/reperfusion for 5 min each
Number of subjects: 10
Study: 28611092

Group type: EXPERIMENTAL
Intervention: CTP‐656 (d9‐ivacaftor)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: d18‐ivacaftor
Number of subjects: 6

Group type: COMPARATOR
Intervention: ivacaftor
Number of subjects: 6
Study: 26282605

Group type: EXPERIMENTAL
Intervention: No-touch (NT) vein graft
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional (C) vein graft
Number of subjects: 54

Group type: COMPARATOR
Intervention: Left internal thoracic artery (LITA)
Number of subjects: 54
Study: 23420231

Group type: EXPERIMENTAL
Intervention: Acupuncture plus rescue medication (cetirizine)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Sham acupuncture plus rescue medication (RM)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Rescue medication (RM) alone
Number of subjects: 422
Study: 20144926

Group type: EXPERIMENTAL
Intervention: Tendon friction rubs (TFR) present at baseline
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Change in TFR at 6 months
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Baseline modified Rodnan skin score (MRSS)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Baseline swollen joint count (SJC)
Number of subjects: 134
Study: 17988917

Group type: EXPERIMENTAL
Intervention: Avaxim 80U‐Pediatric
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Havrix 720
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Havrix followed by Avaxim
Number of subjects: 332
Study: 15557392

Group type: EXPERIMENTAL
Intervention: Acute and large reduction in salt intake from 350 mmol/d to 10 to 20 mmol/d for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progressive increases in salt intake from 10 to 250 mmol/d by a daily amount of 50 mmol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced salt intake (approximately 100 mmol/d) compared with usual salt intake (approximately 170 mmol/d)
Number of subjects: 0
Study: 12545274

Group type: EXPERIMENTAL
Intervention: Mean west African admixture (M) of 0.81 in cases
Number of subjects: 343

Group type: COMPARATOR
Intervention: Mean west African admixture (M) of 0.74 in controls
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Risk ratio for SLE associated with unit change in M
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Adjusted risk ratio for SLE associated with unit change in M after socioeconomic status adjustment
Number of subjects: 343
Study: 10372794

Group type: EXPERIMENTAL
Intervention: High intensity cognitive‐behavioral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low intensity therapy
Number of subjects: 0
Study: 9345439

Group type: EXPERIMENTAL
Intervention: Retrobulbar neuritis
Number of subjects: 223

Group type: COMPARATOR
Intervention: Papillitis
Number of subjects: 223
Study: 1816196

Group type: EXPERIMENTAL
Intervention: norfloxacin 400 mg bid for 10 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: amoxycillin 500 mg bid plus tinidazole 500 mg bid for 15 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: colloidal bismuth subcitrate (CBS) 240 mg bid for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: amoxycillin and tinidazole (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: colloidal bismuth subcitrate (Group III)
Number of subjects: 60
Study: 444355

Group type: EXPERIMENTAL
Intervention: TFX‐SR
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30901046

Group type: EXPERIMENTAL
Intervention: Infant gut microbiome (coabundance scores dominated by Clostridiales)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Infant gut microbiome (Bacteroides‐dominated coabundance grouping)
Number of subjects: 715
Study: 27988427

Group type: EXPERIMENTAL
Intervention: CBT-SAD (social anxiety specific cognitive behavioral therapy)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CBT-GEN (generic cognitive behavioral therapy)
Number of subjects: 125

Group type: COMPARATOR
Intervention: WLC (wait list control)
Number of subjects: 125